Triage Plus was designed to detect mRNAs and DNA single-nucleotide variants from fibroblast growth factor receptor 3 and telomerase reverse transcriptase genes associated with bladder cancer.

Clinicians from Fox Chase Cancer Center at Temple University Health share their highlights from the Society of Urologic ...

The combination of Keytruda and Padcev is taking another major step toward securing its position as a leading therapy in the ...

Kolschowsky Research and Education Institute at Sarasota Memorial Hospital is seeking candidates diagnosed with ...

Armed with new three-year data demonstrating the benefits of Anktiva in a specific patient subset, ImmunityBio is proving its ...

“PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of ...

Merck, Pfizer and Astellas, which in August reported similar results from a Phase 3 study of the combination in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based ...

The phase 3, open-label, single arm BOND-003 trial also evaluated cretostimogene in cohort P with papillary-only high-grade NMIBC who failed prior BCG therapy.

Following the positive outcome, Pfizer and Astellas will seek approval of Padcev-Keytruda in MIBC regardless of a patient’s ...

Dr. Murugesan Manoharan of Miami Cancer Institute and Baptist Health South Florida shares key questions patients who have received a diagnosis of bladder cancer should ask their care team. For ...

Lung cancer screening can detect cancer early when it’s most treatable. See if you qualify for a low-dose CT scan at Fred Hutch.